Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

News & Events

Investors, Press Releases

Philogen annuncia i risultati del primo trimestre 2021

May 12, 2021

Philogen annuncia i risultati del primo trimestre 2021 e fornisce un aggiornamento sui progressi della pipeline

Last News & Events

May 2023 15

Philogen S.p.A. nomina Mediobanca – Banca di Credito Finanziario S.p.A., quale intermediario incaricato dell’esecuzione del programma di acquisto di azioni proprie

May 2023 11

The Board of Directors approves the Net Financial Position for the First Quarter of 2023

  • « Previous
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 95
  • Next »

Privacy Policy / Cookie Policy

  Contacts

  • Follow
  • Follow

Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it